Gretchen Hermann
Brigham and Women's Hospital
15 Papers
51 Citations
Gretchen Hermann is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 5, co-authored 9 publications. Previous affiliations of Gretchen Hermann include Harvard University.
Chat about Author
Papers
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma
Thibaud P. Coroller,Thibaud P. Coroller,Patrick Grossmann,Patrick Grossmann,Ying Hou,Emmanuel Rios Velazquez,Ralph T.H. Leijenaar,Gretchen Hermann,Philippe Lambin,Benjamin Haibe-Kains,Benjamin Haibe-Kains,Raymond H. Mak,Hugo J.W.L. Aerts,Hugo J.W.L. Aerts +13 more
TL;DR: In this article, the authors evaluated computed-tomography (CT) radiomic features for their capability to predict distant metastasis (DM) for lung adenocarcinoma patients.
677
Low Incidence of Chest Wall Pain with a Risk-Adapted Lung Stereotactic Body Radiation Therapy Approach Using Three or Five Fractions Based on Chest Wall Dosimetry
Thibaud P. Coroller,Raymond H. Mak,John H. Lewis,Elizabeth H. Baldini,Aileen B. Chen,Aileen B. Chen,Yolonda L. Colson,Fred Hacker,Gretchen Hermann,David Kozono,E. Mannarino,C. Molodowitch,Jon O. Wee,David J. Sher,Joseph H. Killoran +14 more
TL;DR: Optimization of treatment plans to reduce CW dose and a risk-adapted fractionation strategy of three or five fractions based on the CW V30 resulted in a low incidence of CW toxicity.
EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis
Devarati Mitra,Yu-Hui Chen,Richard Li,Gretchen Hermann,Katelyn M. Atkins,David Kozono,Elizabeth H. Baldini,Ayal A. Aizer,Ugonma Chukwueke,Raymond H. Mak +9 more
TL;DR: Patients with locally advanced EGFR+ NSCLC patients have a high likelihood of brain metastasis, independent of survival duration, and surveillance MRI may allow early identification and treatment ofbrain metastasis.
21
Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer
Richard Li,Richard Li,Gretchen Hermann,Elizabeth H. Baldini,Elizabeth H. Baldini,Aileen B. Chen,Aileen B. Chen,David M. Jackman,David Kozono,David Kozono,Paul Nguyen,Paul Nguyen,Anju Nohria,Anju Nohria,Graham Powell,Raymond H. Mak,Raymond H. Mak +16 more
TL;DR: Patients with locally advanced NSCLC are at high risk for VTE, especially in the first year after treatment initiation, with a 1-year cumulative incidence of 13.5%.
16
Outcomes by EGFR, KRAS, and ALK Genotype After Combined Modality Therapy for Locally Advanced Non–Small-Cell Lung Cancer
Raymond H. Mak,Gretchen Hermann,Hugo J.W.L. Aerts,Elizabeth H. Baldini,Aileen B. Chen,David Kozono,Michael S. Rabin,Scott J. Swanson,Yu-Hui Chen,Paul J. Catalano,Bruce E. Johnson,Pasi A. Jänne +11 more
- 14 May 2018
TL;DR: Analysis of post-recurrence survival demonstrated that EGFR+/ALK+ patients treated with appropriate tyrosine kinase inhibitors had higher OS compared with other groups, and the risk of distant metastases was high in all subgroups.
8